Full Press Release Details
Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
to conduct 1x1 meetings on April 24, 2025
Md., April 21, 2025 - Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"),
a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation
therapy (RT), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). Anatoly Dritschilo, M.D., Chairman of the Board of
Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion.
Dritschilo's presentation will focus on providing an overview and update on the Company's ongoing Phase 2 trial of Ropidoxuridine
and RT for treatment of patients with glioblastoma as well as advancements being made in the Company's Shuttle Diagnostics subsidiary
which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients.
access the live presentation, please use the following information:
MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub
Wednesday, April 23, 2025
2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Track 3 - Chablis at the Paris Hotel & Casino in Las Vegas, NV
you would like to schedule a 1x1 meeting with management, please contact your Planet MicroCap representative or the Company's investor
relations team at 1x1@lythampartners.com. 1x1 meetings will be scheduled and conducted in person at the conference venue: Paris
Hotel & Casino in Las Vegas, NV
Shuttle Pharmaceuticals
in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty
pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve
the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects
of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim
to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements
concerning the development of our company. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including
factors discussed in the "Risk Factors" section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December
31, 2024, filed with the SEC on February 26, 2025, as well other SEC filings. Any forward-looking statements contained in this press
release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims
any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
and Chief Scientific Officer